
|Videos|October 19, 2018
Overcoming BTK Inhibitor Resistance in NHL
Author(s)Julie M. Vose, MD, MBA
Julie M. Vose, MD, MBA, discusses resistance to BTK inhibitors in patients with non-Hodgkin lymphoma.
Advertisement
Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses resistance to BTK inhibitors in patients with non-Hodgkin lymphoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5




















